The legal action, titled Cheng v. Erasca, Inc. (No. 26-cv-03481), alleges that the company and certain executives failed to disclose material information regarding the development of its ERAS-0015 drug candidate. According to the complaint, Erasca allegedly utilized improper preclinical data comparisons to Revolution Medicines, Inc., potentially exposing the firm to patent and trade secret litigation. Plaintiffs contend these omissions undermined the validity of the company’s positive public statements concerning the drug’s potential for treating RAS-mutated solid tumors.
In section Releases
Erasca Investors Face August Deadline in Securities Class Action
Investors who purchased Erasca, Inc. shares between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek appointment as lead plaintiff in a pending securities class action lawsuit filed in the Southern District of California.
Kahn Swick & Foti, LLC, a firm led by former Louisiana Attorney General Charles C. Foti, Jr., is representing the investors. While the August 10 deadline specifically concerns the appointment of a lead plaintiff, the firm notes that individual investors are not required to hold that role to participate in any potential future recovery. Those seeking further information regarding their legal standing or the specifics of the allegations are directed to contact managing partner Lewis Kahn at 1-877-515-1850 or via the firm's dedicated case portal.
Comments (0)
No comments yet. Be the first!